Relay Therapeutics Reports Q2 2025 Financial Results with $677,000 Revenue and $70.4 Million Net Loss

Relay Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $677,000, a significant increase from zero revenue in the same quarter of the previous year. For the six months ending June 30, 2025, the company generated $8.4 million in revenue, down from $10 million in the prior year. The revenue primarily stemmed from the Elevar Agreement, which included the delivery of additional inventory and materials. Despite this revenue, Relay Therapeutics continues to operate at a loss, with a net loss of $70.4 million for the quarter, an improvement from a net loss of $92.2 million in Q2 2024. For the first half of 2025, the net loss was $147.4 million, compared to $173.6 million for the same period in 2024.

Operating expenses for the second quarter of 2025 totaled $77.5 million, down from $100.8 million in the prior year, reflecting a strategic effort to streamline operations. Research and development expenses decreased to $63.9 million from $92 million year-over-year, attributed to cost-saving measures and a shift in focus following the Elevar Agreement. General and administrative expenses also saw a reduction, falling to $13.6 million from $20.1 million. The company’s accumulated deficit reached $1.9 billion as of June 30, 2025, indicating ongoing challenges in achieving profitability.

In terms of operational developments, Relay Therapeutics has made significant strides in its clinical pipeline, particularly with its lead product candidate, RLY-2608, which is in clinical trials for various cancer indications. The company is preparing to initiate a global Phase 3 trial for RLY-2608 in mid-2025. Additionally, Relay Therapeutics has expanded its research focus to include genetic diseases, with ongoing development of other product candidates such as RLY-8161 for NRAS-mutated solid tumors.

The company’s financial position remains stable, with cash, cash equivalents, and investments totaling $656.8 million as of June 30, 2025. This amount is expected to fund operations into 2029, although Relay Therapeutics acknowledges the need for additional capital to support ongoing and future development activities. The company has not yet generated revenue from product sales and anticipates continued operating losses as it advances its clinical programs. Relay Therapeutics is actively exploring various financing options, including public or private equity, debt financing, and potential collaborations to secure the necessary funds for its operations.